Posted inClinical Updates news Oncology Specialties
First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial
The IMforte phase 3 trial demonstrates that lurbinectedin plus atezolizumab as first-line maintenance significantly prolongs progression-free and overall survival in extensive-stage small-cell lung cancer, albeit with increased hematologic toxicity.